dacetuzumab + rituximab + gemcitabine

Dacetuzumab + rituximab + gemcitabine is a combination regimen studied for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL)[1][5][7]. Dacetuzumab is a humanized monoclonal antibody targeting CD40, mediating its antitumor effect via effector cell functions (including antibody-dependent cellular cytotoxicity and phagocytosis) and direct apoptotic signal transduction[1][7]. Rituximab is a monoclonal antibody targeting CD20 on B-cells, leading to cell death primarily via immune-mediated mechanisms. Gemcitabine is a nucleoside antimetabolite chemotherapy that inhibits DNA synthesis in rapidly dividing cells[3][9]. The combination has shown synergistic activity in preclinical studies and promising response rates in phase 1b clinical trials for heavily pre-treated DLBCL patients[1][5][7]. Dacetuzumab is investigational and not approved for this indication. Common adverse events include nausea, thrombocytopenia, fatigue, headache, and cytokine release syndrome[1][7].

Brand names

Rituxan (rituximab)Gemzar (gemcitabine)

Other names

dacetuzumab + rituximab + gemcitabine